TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides

Официальное название

TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides: a Prospective Randomized Controlled Study

Обзор

Primary cutaneous T-cell lymphomas are a group of peripheral T-cell lymphomas that primarily involve the skin. Mycosis fungoides (MF) is the most frequent subtype. Most patients with early-stage MF (i.e., patches and plaques of the skin without extracutaneous involvement) have a good prognosis but a subset of patients progress to incurable advanced-stage disease with an overall survival (OS) less than 5 years and an impaired quality of life. We have recently identified the tumor clone frequency in lesional skin (measured by high-throughput sequencing of the TCRB locus) as the most important prognostic factor of progression-free survival (PFS) and OS in a retrospective analysis on 210 patients with early-stage MF (p\<0.001). Phototherapy is a standard therapeutic option in early-stage MF but fails to eradicate the tumor clone from the skin. Low-dose total-skin electron-beam therapy (LDTSEBT, 12 Gy over a 3-week period) has been shown to be safe and highly effective in MF with an 88% overall response rate and a better safety profile compared to standard-dose total-skin electron-beam therapy, in a pooled analysis from 3 phase II trials on 33 patients and a retrospective analysis of 12 patients treated with LDTSEBT. We hypothesize that the use of LDTSEBT is associated with a significantly higher 1-year PFS compared to conventional treatment with phototherapy. Our secondary hypotheses are that LDTSEBT is associated with a higher tumor T-cell clone eradication compared to phototherapy, and improves OS and quality of life in patients with skin-limited MF. The main objective of this study is therefore to prospectively determine if LDTSEBT is associated with a higher 1-year progression-free survival in patients with early-stage mycosis fungoides, compared to conventional treatment with phototherapy. The primary endpoint is PFS at 12 months after study inclusion.

Вмешательства

• Другое Low-dose total-skin electron-beam therapy
  Low-dose total skin electron beam therapy (12 Gy) will be delivered to the patient in 4 Gy/week, 1 Gy/day over 3 weeks by symmetrical electron beams of 6 MeV energy via a linac accelerator.
• Другое Phototherapy
  Phototherapy will be given 3 times a week during 2 months, then twice a week during one month, then once a week during one month, or until disease progression or unacceptable side effect, whatever comes first. Patients with plaques will receive PUVA therapy and patients with patches only will receive narrow-band UVB therapy.

Первичные конечные точки

• Progression free survival [Срок оценки: at 12 months]

Вторичные конечные точки (12)

• Proportion of patients with tumor clone eradication in skin [Срок оценки: at 4 months after inclusion]
• Complete response rate [Срок оценки: at 4 months after inclusion]
• Overall response rates [Срок оценки: at 4 months after inclusion]
• Progression-free survival [Срок оценки: at 5 years post inclusion]
• Overall survival [Срок оценки: at 5 years post inclusion]
• Quality of life as measured by the EORTC QLQ-C30 [Срок оценки: at inclusion]
• Quality of life as measured by the EORTC QLQ-C30 [Срок оценки: at 1 month]
• Quality of life as measured by the EORTC QLQ-C30 [Срок оценки: at 4 months]
• Quality of life as measured by the EORTC QLQ-C30 [Срок оценки: at 1 year]
• Quality of life as measured by the EORTC QLQ-C30 [Срок оценки: at 2 years]
• Quality of life as measured by the EORTC QLQ-C30 [Срок оценки: at 3 years]
• Quality of life as measured by the EORTC QLQ-C30 [Срок оценки: at 4 years]

Критерии участия

Критерии включения

• Age ≥ 18 years
• Histopathologically confirmed diagnosis of International Society for Cutaneous Lymphomas (ISCL) / European Organisation for Research and Treatment of Cancer (EORTC) mycosis fungoides stage IB or IIA

Критерии исключения

• Poor performance status: WHO performance status score > 2
• Physically unable to maintain the posture
• Patient with no health coverage
• Patient under guardianship or curatorship
• Previous history of dose-limiting radiation therapy in the field
• Previous history of dose-limiting phototherapy
• Previous history of melanoma, skin squamous cell carcinoma or basal cell carcinoma or other absolute contraindication to phototherapy (including a history of lupus, xeroderma pigmentosum, or porphyria)
• Pregnant or breastfeeding woman
• Contraindication to methoxsalen (severe liver, renal or heart failure)

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Другое

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT05205902 · APHP200128

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗